Breast reduction surgery and breast cancer risk: Does reduction mammaplasty have a role in primary prevention strategies for women at high risk of breast cancer? Discussion

Plastic and Reconstructive Surgery

Volumn 113, Issue 7, 2004, Pages 2111-2112

  Orgill, Dennis P ^a,b   Iglehart, J Dirk ^a   Gelman, Rebecca ^a  

^a Brigham and Women's Hospital ^*

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BODY MASS; BREAST CANCER; BREAST REDUCTION; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CANCER SCREENING; CANCER SUSCEPTIBILITY; CLINICAL PRACTICE; EVALUATION; FOLLOW UP; GENE MUTATION; GENETIC PREDISPOSITION; HIGH RISK PATIENT; HUMAN; MAMMOGRAPHY; NOTE; ONCOGENE; OUTCOMES RESEARCH; PRIMARY PREVENTION; PRIORITY JOURNAL; RISK ASSESSMENT; SURGICAL TECHNIQUE;

EID: 4444302757     PISSN: 00321052     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.PRS.0000122561.55867.D6     Document Type: Note

References (8)

1. Haffty, B. G., Harrold, E., Kahn, A. J., et al. Outcome of conservatively managed early-onset breast cancer by BRCA1/2 status. Lancet 359: 1471, 2002.
2. Frisell, J., Glas, U., Hellstrom, L., and Somell, A. Randomized mammographic screening for breast cancer in Stockholm. Breast Cancer Res. Treat. 8: 45, 1986.
3. Bailar, J. Hormone-replacement therapy and cardiovascular diseases. N. Engl. J. Med. 349: 521, 2003.
4. Hartmann, L. C., Sellers, T. A., Schaid, D. J., et al. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J. Natl. Cancer Inst. 93: 1633, 2001.
5. Narod, S. A., Brunet, J. S., Ghadirian, P., et al. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: A case-control study. Lancet 356: 1876, 2000.
6. King, M. C., Wieand, S., Hale, K., et al. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. J.A.M.A. 286: 2251, 2001.
7. Narod, S. A., Brunet, S. J., Ghadirian, P., et al. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: A case control study. Lancet 356: 1976, 2000.
8. Rebbeck, T. R., Lynch, H. T., Neuhausen, S. L., et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N. Engl. J. Med. 346: 1616, 2002.